<--- Back to Details
First PageDocument Content
Genetics / Personalized medicine / Pharmacology / Trastuzumab / Melanoma / Breast cancer / Vemurafenib / BRAF / Targeted therapy / Medicine / Biology / Evidence-based medicine
Date: 2014-06-09 16:45:23
Genetics
Personalized medicine
Pharmacology
Trastuzumab
Melanoma
Breast cancer
Vemurafenib
BRAF
Targeted therapy
Medicine
Biology
Evidence-based medicine

Add to Reading List

Source URL: www.personalizedmedicinecoalition.org

Download Document from Source Website

File Size: 906,59 KB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document